Belgium-based UCB (Euronext Brussels: UCB) has entered into a definitive agreement to acquire US-based Neurona Therapeutics, a privately held clinical-stage company, for up to USD 1.15 billion. The transaction extends UCB's epilepsy franchise beyond symptomatic management into regenerative cell therapy, anchored by Neurona's lead asset NRTX-1001, an allogeneic GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy (mTLE).

UCB will pay USD 650 million upfront, with up to USD 500 million in potential future milestone payments. The milestone breakdown across development, regulatory, and commercial triggers was not disclosed. The transaction is global in scope, as UCB acquires Neurona in its entirety, and is expected to close by end of Q2 2026, subject to antitrust clearance and customary closing conditions. UCB confirmed that its 2026 revenue guidance remains unchanged, with adjusted EBITDA now expected to grow in a high single-digit to mid-teens percentage range at constant exchange rates.

NRTX-1001 and the GABAergic interneuron platform

NRTX-1001 is derived from a human pluripotent stem cell line and differentiated into high-purity inhibitory interneurons that produce gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system. In mTLE, hyperexcitable neural networks in the hippocampal formation generate recurrent seizures that resist conventional antiseizure medications in approximately one-third of patients. Rather than modulating receptor activity pharmacologically, NRTX-1001 is administered as a single image-guided intracerebral dose intended to engraft within the epileptic focus, restore inhibitory tone, and rebalance excitatory-inhibitory circuitry at the structural level.

NRTX-1001 is currently being evaluated across two active clinical programs. The EPIC trial (NCT05135091) is a Phase III study in drug-resistant unilateral mTLE, designed with a sham comparator, which positions it as a potentially registrational study. A separate Phase I/II trial (NCT06422923) is recruiting patients with drug-resistant bilateral mTLE, extending the addressable population beyond the unilateral indication. Both studies evaluate safety, tolerability, and effects on seizure frequency.

NRTX-1001 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for drug-resistant mTLE and PRIME designation from the EMA for adults with drug-resistant focal epilepsy.

The underlying platform uses pluripotent stem cell technology to generate medial ganglionic eminence (MGE)-type GABAergic interneurons, the specific subtype depleted in epileptic foci. This selectivity distinguishes the approach from broader inhibitory modulation strategies and underpins the rationale for durable, focal seizure control following a single administration.

Competitive landscape and strategic outlook

Mesial temporal lobe epilepsy is the most common form of focal epilepsy and carries substantial burden across cognition, memory, behavior, and daily functioning. Current pharmacological options address symptom frequency rather than the underlying circuitry deficit, and resective surgery — the standard non-pharmacological intervention — is not appropriate for bilateral disease and carries its own procedural risk profile. The structural repair thesis embedded in NRTX-1001's mechanism addresses a gap that neither antiseizure medications nor surgical resection resolves.

For UCB, which generated EUR 7.7 billion in revenue in 2025 across approximately 40 countries, the acquisition consolidates a strategic position in epilepsy that the company has maintained for over three decades. UCB's existing epilepsy portfolio comprises approved antiseizure therapies; NRTX-1001 represents a modality shift toward disease modification rather than symptomatic control. The Phase III EPIC trial's sham-controlled design provides a pathway to a regulatory filing that, if successful, would position UCB with the first approved interneuron cell therapy for a focal epilepsy indication.

The broader interneuron regenerative platform retains optionality for CNS indications beyond mTLE, though no additional named clinical programs were disclosed in connection with this transaction. The deal's milestone structure preserves contingent value tied to NRTX-1001's clinical and regulatory progression, aligning UCB's incremental financial exposure with the asset's de-risking trajectory.

---

Spot something wrong? Report an issue with this article